- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Eye therapy, glaucoma products receive approvable letters
Rochester, NY-The FDA has issued approvable letters to Bausch & Lomb for loteprednol etabonate and tobramycin ophthalmic suspension (ZyLET), and Allergan Inc. for its bimatoprost 0.03%/timolol 0.05% solution (Lumigan).
Rochester, NY-The FDA has issued approvable letters to Bausch & Lomb for loteprednol etabonate and tobramycin ophthalmic suspension (ZyLET), and Allergan Inc. for its bimatoprost 0.03%/timolol 0.05% solution (Lumigan).
The approvable letters outline the parameters the companies must meet to obtain final marketing approval.
Bausch & Lomb's product is a combination therapy for patients with steroid-responsive inflammatory ocular conditions who have or are at risk of developing superficial bacterial ocular infections.
Allergan's product is a treatment for glaucoma. The company said the FDA's letter indicated the need for additional clinical investigation. That study is expected to conclude by the end of 2004.
